retatrutide clinical trial phase retatrutide Eli Lilly and Company's triple agonist, retatrutide, successful in two additional 3 obesity trials, delivering significant improvements in weight and A1C retatrutide phase 2 trial results
Pay in 4 interest-free payments of $5.63 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21















)











